241 related articles for article (PubMed ID: 36557826)
21. Pharmacophore modeling improves virtual screening for novel peroxisome proliferator-activated receptor-gamma ligands.
Lewis SN; Garcia Z; Hontecillas R; Bassaganya-Riera J; Bevan DR
J Comput Aided Mol Des; 2015 May; 29(5):421-39. PubMed ID: 25616366
[TBL] [Abstract][Full Text] [Related]
22. The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.
Behm DJ; Stankus G; Doe CP; Willette RN; Sarau HM; Foley JJ; Schmidt DB; Nuthulaganti P; Fornwald JA; Ames RS; Lambert DG; Calo' G; Camarda V; Aiyar NV; Douglas SA
Br J Pharmacol; 2006 May; 148(2):173-90. PubMed ID: 16547525
[TBL] [Abstract][Full Text] [Related]
23. Exploration of the urocontrin A scaffold yields new urotensinergic system allosteric modulator and competitive antagonists.
Billard E; Hébert TE; Chatenet D
Biochem Pharmacol; 2023 May; 211():115485. PubMed ID: 36889446
[TBL] [Abstract][Full Text] [Related]
24. On the value of homology models for virtual screening: discovering hCXCR3 antagonists by pharmacophore-based and structure-based approaches.
Huang D; Gu Q; Ge H; Ye J; Salam NK; Hagler A; Chen H; Xu J
J Chem Inf Model; 2012 May; 52(5):1356-66. PubMed ID: 22545675
[TBL] [Abstract][Full Text] [Related]
25. Lead generation of cysteine based mesenchymal epithelial transition (c-Met) kinase inhibitors: Using structure-based scaffold hopping, 3D-QSAR pharmacophore modeling, virtual screening, molecular docking, and molecular dynamics simulation.
Raafat A; Mowafy S; Abouseri SM; Fouad MA; Farag NA
Comput Biol Med; 2022 Jul; 146():105526. PubMed ID: 35487125
[TBL] [Abstract][Full Text] [Related]
26. Novel Scaffolds for Modulation of NOD2 Identified by Pharmacophore-Based Virtual Screening.
Guzelj S; Tomašič T; Jakopin Ž
Biomolecules; 2022 Jul; 12(8):. PubMed ID: 36008948
[TBL] [Abstract][Full Text] [Related]
27. In silico discovery of food-derived phytochemicals against asialoglycoprotein receptor 1 for treatment of hypercholesterolemia: Pharmacophore modeling, molecular docking and molecular dynamics simulation approach.
Gao S; Wang L; Bai F; Xu S
J Mol Graph Model; 2023 Dec; 125():108614. PubMed ID: 37651861
[TBL] [Abstract][Full Text] [Related]
28. Developing a Naïve Bayesian Classification Model with PI3Kγ structural features for virtual screening against PI3Kγ: Combining molecular docking and pharmacophore based on multiple PI3Kγ conformations.
Jiang Y; Xiong W; Jia L; Xu L; Cai Y; Chen Y; Jin J; Gao M; Zhu J
Eur J Med Chem; 2022 Dec; 244():114824. PubMed ID: 36257282
[TBL] [Abstract][Full Text] [Related]
29. Discovery of novel RARα agonists using pharmacophore-based virtual screening, molecular docking, and molecular dynamics simulation studies.
Ghorayshian A; Danesh M; Mostashari-Rad T; Fassihi A
PLoS One; 2023; 18(8):e0289046. PubMed ID: 37616260
[TBL] [Abstract][Full Text] [Related]
30. Optimization of virtual screening against phosphoinositide 3-kinase delta: Integration of common feature pharmacophore and multicomplex-based molecular docking.
Zhu J; Meng H; Li X; Jia L; Xu L; Cai Y; Chen Y; Jin J; Yu L
Comput Biol Chem; 2024 Apr; 109():108011. PubMed ID: 38198965
[TBL] [Abstract][Full Text] [Related]
31. Structure-based virtual screening of the nociceptin receptor: hybrid docking and shape-based approaches for improved hit identification.
Daga PR; Polgar WE; Zaveri NT
J Chem Inf Model; 2014 Oct; 54(10):2732-43. PubMed ID: 25148595
[TBL] [Abstract][Full Text] [Related]
32. Multiple e-Pharmacophore modeling to identify a single molecule that could target both streptomycin and paromomycin binding sites for 30S ribosomal subunit inhibition.
C P A; Subhramanian S; Sizochenko N; Melge AR; Leszczynski J; Mohan CG
J Biomol Struct Dyn; 2019 Apr; 37(6):1582-1596. PubMed ID: 29633917
[TBL] [Abstract][Full Text] [Related]
33. Identification of potential inhibitors for HCV NS5b of genotype 4a by combining dynamic simulation, protein-ligand interaction fingerprint, 3D pharmacophore, docking and 3D QSAR.
El-Hassab MAE; El-Bastawissy EE; El-Moselhy TF
J Biomol Struct Dyn; 2020 Sep; 38(15):4521-4535. PubMed ID: 31647392
[TBL] [Abstract][Full Text] [Related]
34. Increased expression of urotensin II, urotensin II-related peptide and urotensin II receptor mRNAs in the cardiovascular organs of hypertensive rats: comparison with endothelin-1.
Hirose T; Takahashi K; Mori N; Nakayama T; Kikuya M; Ohkubo T; Kohzuki M; Totsune K; Imai Y
Peptides; 2009 Jun; 30(6):1124-9. PubMed ID: 19463745
[TBL] [Abstract][Full Text] [Related]
35. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
Islam MA; Pillay TS
J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
[TBL] [Abstract][Full Text] [Related]
36. Ligand-based pharmacophore modeling of TNF-α to design novel inhibitors using virtual screening and molecular dynamics.
Jade DD; Pandey R; Kumar R; Gupta D
J Biomol Struct Dyn; 2022 Mar; 40(4):1702-1718. PubMed ID: 33034255
[TBL] [Abstract][Full Text] [Related]
37. Predicted ligands for the human urotensin-II G protein-coupled receptor with some experimental validation.
Kim SK; Goddard WA; Yi KY; Lee BH; Lim CJ; Trzaskowski B
ChemMedChem; 2014 Aug; 9(8):1732-43. PubMed ID: 24989481
[TBL] [Abstract][Full Text] [Related]
38. In silico analysis of marine natural product for protein arginine methyltransferase 5(PRMT5) inhibitors based on pharmacophore and molecular docking.
Luo L; Tan H; Liao Y
J Biomol Struct Dyn; 2023; 41(22):13180-13197. PubMed ID: 36856049
[TBL] [Abstract][Full Text] [Related]
39. Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2
Musoev A; Numonov S; You Z; Gao H
Molecules; 2019 Aug; 24(16):. PubMed ID: 31394858
[TBL] [Abstract][Full Text] [Related]
40. Discovery of promising FtsZ inhibitors by E-pharmacophore, 3D-QSAR, molecular docking study, and molecular dynamics simulation.
Qiu Y; Zhou L; Hu Y; Bao Y
J Recept Signal Transduct Res; 2019 Apr; 39(2):154-166. PubMed ID: 31355691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
